At Sunovion, we are advancing therapies to tackle some of the most challenging psychiatric and neurological disorders that impact the lives of millions of people worldwide. As a patient-centered company, we focus on improving the quality of life for those living with serious CNS conditions. Within a decade, we have introduced several new treatment options and will continue expanding our portfolio to enable better outcomes for those we serve. Innovation today, healthier tomorrows.
Vision & Values
Our mission, vision and values are foundational to our purpose and drive our innovative medicines. These principles inspire our culture and foster collaboration, trust, and a passion to serve patients. We strive to contribute to society through the novel application of science and medicine to support a healthy future for people around the globe.
Sunovion By the Numbers
Historically, have been ranked fastest growing among top U.S. pharmaceutical companies*
Employee Volunteer hours over 10 years
Bringing together diverse experiences, our people are the cornerstone of Sunovion and shape our culture while advancing our success. With their combined talent and dedication, they align, collaborate and win as one team.
Diversity & Inclusion
Sunovion is committed to embracing diversity and inclusion in everything we do. Our team brings a wide variety of experiences and approaches to work, allowing us to offer our patients the most innovative and effective solutions.
Because we believe in supporting the communities where we live and work, we partner with local organizations who share our passion. Far more than a commitment, we consider it our responsibility to make our world stronger and healthier.
Our History of Innovation
For more than a decade, we have innovated clinical advances and new treatment options for people living with serious psychiatric and neurological conditions. We continue to develop and support leading advocacy programs and community initiatives focused on improving health care. Building on a legacy of medical science discoveries and treatments for patients remains our goal.
CEO Antony Loebel, M.D. signs the “CEO Action for Diversity & Inclusion” to continue our commitment to advance D&I in the workplace
Sunovion Answers is named a J.D. Power Certified Customer Service Program (SM)
Sunovion, Sumitomo Pharma Co., Ltd and Otsuka enter worldwide development and commercialization collaboration
Sunovion named Gold Stevie® Winner and "Employer of the Year" for Great Employers in The Stevie® Awards
FDA approves KYNMOBI® (apomorphine hydrochloride) sublingual film for the treatment of OFF episodes associated with Parkinson's disease (PD)
KYNMOBI® is launched in U.S.
New England Journal of Medicine publishes pivotal results evaluating SEP-363856 for treatment of schizophrenia
Health Canada approves KYNMOBI®
Sunovion Answers named a J.D. Power Certified Customer Service ProgramSM for third time
Sunovion Hands On! Annual Community Service Program contributes more than 30,000 employee volunteer hours in 439 projects in eight years to community organizations and relief efforts
Sunovion Answers named a J.D. Power Certified Customer Service ProgramSM for second time
FDA accepts resubmitted NDA for APL-130277
SEP-363856 receives FDA Breakthrough Therapy Designation
Sunovion and The Advanced Math & Science Academy (AMSA) Charter School begin STEM partnership to inspire next generation of innovators
Sunovion Hands On! Community Service Program contributes 25,000+ volunteer hours in 415+ projects in seven years
Receives Corporate Social Responsibility Award, United Way of Tri-County, 2018
Receives FDA approval of supplemental NDA for use of Latuda® in treatment of bipolar depression in pediatric patients
Lonhala® Magnair® becomes available in U.S.
Health Canada approves Latuda® to treat adolescents with bipolar depression
Health Canada Approves Aptiom® (eslicarbazepine acetate) as Monotherapy
Health Canada Approves of Aptiom® (eslicarbazepine acetate) as Adjunctive Therapy
Receives FDA approval for Latuda® to treat adolescents with schizophrenia
Sunovion Answers becomes a J.D. Power Certified Customer Service ProgramSM
Establish partnership with Boston Red Sox and Red Sox Foundation
Health Canada approves Latuda® to treat adolescents with schizophrenia
Receives FDA approval for Aptiom® for expanded indication to treat partial-onset seizures in children and adolescents
Receives FDA approval for Lonhala® Magnair® Inhalation Solution to treat COPD
Sunovion ranks as second-fastest growing pharmaceutical company*
“Lead the Way to a Healthier World” established as the Company’s vision
Receives Corporate Responsibility Award, United Way of Tri-County, 2016
Complete acquisition of Cynapsus Therapeutics and its product candidate
Honored with The JED Foundation Corporate Leadership Award for leadership in mental health
Won SCRIP Award for Management Team of the Year
Received Silver Stevie Award: Global Clinical Development Organization, American Business Awards (The Stevies)
Received FDA approval for Aptiom® as monotherapy for partial-onset seizures
Health Canada approves Aptiom® as once-daily adjunctive treatment
Aptiom® is launched in the U.S.
FDA approves Latuda® as monotherapy and adjunctive therapy in adults with bipolar depression
Receives FDA approval of Aptiom® (eslicarbazepine acetate) as adjunctive treatment of partial-onset seizures
Becomes inaugural member of Massachusetts Life Sciences Center Neuroscience Consortium
Complete acquisition of Elevation Pharmaceuticals
Launches annual Hands On! community service program to give back where employees live and work
Health Canada approves Latuda® for schizophrenia in adults
Announces partnership with CARE Inc., an international humanitarian agency, to help improve the health and lives of those in need
Latuda® becomes available for the treatment of adult patients with schizophrenia
Sunovion is established (October 2010) following the integration of Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc., former U.S. operations of Sunovion’s parent company Sumitomo Dainippon Pharma Co., Ltd.
The FDA approves Latuda® (lurasidone HCl) for the treatment of adult patients with schizophrenia